Summary & Overview
HCPCS G9129: Oncology Disease-Status Assessment for Multiple Myeloma
HCPCS Level II code G9129 identifies an oncology disease-status assessment limited to multiple myeloma and systemic disease at stage II or higher for use within a Medicare-approved demonstration project. This code captures evaluations that document disease stage and progression in patients with advanced multiple myeloma or systemic malignancies, supporting clinical tracking and demonstration-related reporting. Nationally, the code matters because it standardizes reporting of advanced disease-status assessments in a defined demonstration context, aiding comparability across participating sites and payers.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical intent of the code, expected sites of service, common modifiers associated with HCPCS submissions, and guidance on payer coverage landscape where available. The publication outlines benchmarks and policy-relevant considerations for demonstration-project reporting, summarizes typical billing practices for advanced oncology disease-status evaluation, and provides context for clinical teams and billing departments on where this code fits within oncology service lines. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G9129 denotes a service related to oncology disease status assessment limited to multiple myeloma and systemic disease at stage II or higher, intended for use within a Medicare-approved demonstration project. The service type is an oncology disease status evaluation, focused on determining disease stage and progression in patients with advanced multiple myeloma or systemic malignancy. The typical site of service is an oncology clinic or hospital outpatient setting, where specialty cancer assessments and staging evaluations are performed.
Clinical & Coding Specifications
Clinical Context
A 68-year-old Medicare beneficiary with known multiple myeloma (previously diagnosed with bone marrow biopsy and serum/urine protein studies) presents to an oncology clinic enrolled in a Medicare-approved demonstration project evaluating disease status reporting for systemic malignancies. The patient has progressive symptoms (fatigue, new bone pain, rising M-protein) and recent imaging showing lytic lesions. The oncology advanced practice nurse and medical oncologist perform a focused disease-status assessment during an outpatient visit: review of interval history, targeted physical exam, review of recent laboratory results (CBC, CMP, serum free light chains), review of quantitative immunoglobulin/serum protein electrophoresis, and documentation of staging consistent with Stage II or higher systemic disease. The clinical workflow includes verifying project eligibility, obtaining consent for data reporting per the demonstration protocol, completing structured disease-status documentation in the electronic health record with explicit stage assignment (Stage II or greater), and submitting the appropriate administrative claim line using G9129 to capture the disease-status reporting activity under the demonstration project. Ancillary services (imaging review, lab orders) may occur same day; separate charges for those services are billed with their own CPT/HCPCS codes. Typical site of service is outpatient oncology clinic or hospital-based outpatient infusion center participating in the Medicare demonstration project.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|